VVC Holdings

VVC Holdings, often operating through its primary entity Vaxcyte (formerly SutroVax), is a clinical-stage biotechnology company specializing in the development of next-generation conjugate vaccines. The company utilizes a proprietary site-specific protein-polysaccharide conjugation platform to create vaccines that target complex infectious diseases, with a primary focus on pneumococcal disease. Their lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to provide broader protection than current standards of care. Beyond respiratory infections, the company is also exploring applications for its technology in treating conditions like periodontitis.